Humira (Adalimumab) for Crohn's Disease: A Patient Guide

Humira (adalimumab) has been one of the most widely prescribed biologics for Crohn's disease for nearly two decades, and it remains a cornerstone of treatment even as newer options have joined the lineup. Whether you are about to start adalimumab, have been on it for years, or are navigating a switch to one of its biosimilars, understanding the evidence behind this drug - and the practical realities of living with it - can help you have better conversations with your GI team and feel more confident in your treatment plan.

Key Takeaways

• In the landmark CHARM trial, 40% of Crohn's patients on adalimumab every other week achieved clinical remission at week 26 versus 17% on placebo (P less than 0.001) (1)
• The PYRAMID Registry showed that 75% of adalimumab-naive patients reached remission by year 6, suggesting sustained long-term benefit (3)
• A higher induction dose did not improve outcomes in the 2022 SERENE-CD trial - the standard regimen remains the recommended approach (2)
• Multiple biosimilars are now available, and real-world studies show 30-month treatment persistence of 88% after switching, comparable to the originator (5)
• Adalimumab is a subcutaneous injection that most patients learn to give themselves at home, making it one of the more convenient biologic options

What Humira Is and How It Works for Crohn's Disease

Adalimumab is a fully human monoclonal antibody that targets tumor necrosis factor alpha (TNF-alpha), a protein that drives inflammation in the gut. By binding to TNF-alpha and blocking its effects, adalimumab helps reduce the immune system's overactive response that causes the tissue damage, ulcers, and symptoms of Crohn's disease. It is FDA-approved to induce and maintain remission in adults and children with moderate to severe Crohn's disease, including patients who have not responded to conventional therapies like corticosteroids and immunomodulators (7).

The Anti-TNF Mechanism in Plain Language

Think of TNF-alpha as a chemical alarm signal your immune system sends to recruit inflammatory cells to your intestinal lining. In Crohn's disease, this alarm gets stuck in the "on" position even when there is no infection to fight. Adalimumab works by attaching itself to TNF-alpha molecules before they can reach their targets, effectively turning down the volume on that alarm. This does not shut off your immune system entirely - it specifically quiets the TNF-driven pathway that is causing the most damage. For a broader look at how this class of drugs works, see our overview of anti-TNF therapies in Crohn's disease.

Where Humira Fits Among Today's Crohn's Biologics

Adalimumab sits in the same anti-TNF class as infliximab (Remicade) and certolizumab pegol (Cimzia). Today it also competes with newer options including ustekinumab (Stelara), risankizumab (Skyrizi), vedolizumab (Entyvio), guselkumab (Tremfya), and JAK inhibitors like upadacitinib. What sets adalimumab apart is its combination of a long evidence track record, subcutaneous delivery that allows home injection, and now an extensive biosimilar market that is making it more affordable. For a deeper comparison of how these biologics stack up, take a look at our guide to choosing the best biologic for Crohn's disease.

Efficacy Evidence: What Clinical Trials Show

The evidence behind adalimumab spans nearly 20 years, from early trials to long-term real-world registries. Here is what the key studies tell us about how well this drug works - and for whom.

CHARM: The 26- and 56-Week Maintenance Data

The CHARM trial remains the landmark maintenance study for adalimumab in Crohn's. At week 26, 40% of patients receiving adalimumab every other week and 47% receiving it weekly achieved clinical remission, compared to just 17% on placebo. At week 56, the remission rates were 36% and 41% for the every-other-week and weekly groups respectively, versus only 12% on placebo (P less than 0.001 at both timepoints) (1). These results established adalimumab as an effective long-term option and helped shape the every-other-week maintenance dosing that most patients use today.

PYRAMID Registry: Six-Year Real-World Outcomes

Clinical trials use strict entry criteria, so real-world data helps confirm whether those results hold in everyday practice. The PYRAMID Registry followed adalimumab-naive Crohn's patients for up to six years and found that the proportion achieving Harvey-Bradshaw Index remission (HBI less than 5) actually increased over time - from 68% at year 1 to 75% by year 6 (3). This suggests that patients who respond to adalimumab and stay on it tend to do well over the long term.

SERENE-CD: Does a Higher Induction Dose Help?

A natural question is whether giving more drug upfront leads to better outcomes. The 2022 SERENE-CD phase 3 trial tested a higher induction regimen (160 mg at weeks 0, 1, 2, and 3) against the standard dosing. The answer was clear: clinical remission at week 4 was 44% in both arms, with no additional benefit from the higher dose (2). The trial also found that therapeutic drug monitoring during maintenance did not outperform clinical adjustment alone. In practical terms, this means the standard induction schedule remains the right starting point.

Perianal Fistulas: What Long-Term Data Show

Perianal fistulas are among the most difficult complications of Crohn's disease, and adalimumab has meaningful evidence here. In a dedicated fistula analysis, roughly 60% (22 of 37) of adalimumab-treated patients had healed draining fistulas after 2 years, and 90% (28 of 31) of those whose fistulas closed by week 56 maintained closure through the following year of open-label therapy (4). It is worth noting that head-to-head evidence suggests infliximab may have a slight edge over adalimumab specifically for first-line perianal fistula treatment, which is something to discuss with your GI team if fistulas are your primary concern.

Humira Dosing Schedule and Self-Injection

One of the practical advantages of adalimumab is that it is given as a subcutaneous injection - a shot under the skin that most patients can learn to give themselves at home after training. No infusion center visits required.

The Standard Induction and Maintenance Schedule

The FDA-labeled Crohn's dosing for adults is (7):

• Day 1: 160 mg (four 40 mg injections)
• Day 15: 80 mg (two 40 mg injections)
• Day 29 onward: 40 mg every other week

The first dose is often the most daunting because of the volume of injections, but your GI team or specialty nurse will typically walk you through it. Some patients give the day 1 doses in the clinic, and by day 15 they feel more comfortable handling the injection at home.

How to Inject Humira Safely at Home

Injections go under the skin of the abdomen (at least two inches from the navel) or the front of the thigh. Rotate your injection site each time to reduce irritation. The medication comes in pre-filled pens or syringes - the pen is the most common format and involves pressing the device against the skin and clicking a button. Let the pen or syringe reach room temperature for about 15 to 30 minutes before injecting, as cold medication can sting more.

Missed Doses, Storage, and Travel Tips

If you miss a dose, inject it as soon as you remember, then resume your regular every-other-week schedule. Do not double up. Store adalimumab in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit), protected from light, and never freeze it. For travel, a single dose may be kept at room temperature for a limited time according to the label - a small insulated travel case with a cold pack is the standard approach for flights and trips. Some patients use dose escalation to weekly injections if their response begins to fade, which the label allows and your doctor can guide.

Side Effects, Risks, and Black Box Warnings

Adalimumab is generally well tolerated by most patients, but it carries important safety information that every patient should understand before starting.

The FDA Boxed Warnings

The FDA requires boxed warnings (the most serious category) on adalimumab for two areas: serious infections and malignancy. Serious infections can include tuberculosis, invasive fungal infections, and bacterial sepsis. The malignancy warning covers lymphoma, including a rare form called hepatosplenic T-cell lymphoma (HSTCL) that has been reported primarily in adolescent and young adult males with IBD who were also receiving azathioprine or 6-mercaptopurine (7). These are rare but real risks, and they are part of the reason your doctor orders screening tests before you start.

Common Day-to-Day Side Effects

The most frequently reported side effects are injection site reactions (redness, itching, or mild swelling at the injection spot), upper respiratory infections, headaches, rash, and nausea (7). Injection site reactions tend to be mild and often improve after the first few doses as patients refine their technique and injection routine.

Screening and Monitoring Before You Start

Before beginning adalimumab, standard practice includes latent tuberculosis testing (usually a skin test or blood test), hepatitis B screening, and a review of your vaccinations. Live vaccines - including the live shingles vaccine (Zostavax), MMR, and the nasal flu spray - should be avoided while on treatment. Make sure to tell your care team promptly about fever, persistent cough, unusual bruising or bleeding, or any signs of infection.

Biosimilars and What Switching Means for You

If you have been on adalimumab for a while, there is a good chance you have already heard from your insurer, pharmacy, or GI team about switching to a biosimilar. Here is what you need to know.

Why Biosimilars Exist and How They Are Approved

Humira's US patent protections ended in 2023, and multiple adalimumab biosimilars are now on the market - including products with FDA interchangeable status. Biosimilars are rigorously tested copies of the originator biologic, shown to have no clinically meaningful differences in safety, efficacy, or immunogenicity. Insurers and health systems often move patients to biosimilars for cost reasons, a practice called non-medical switching. For a comprehensive look at how biosimilars work and what interchangeability means, see our dedicated biosimilars patient guide.

Real-World Outcomes When Patients Switch

A 2024 real-world Canadian study of mandatory non-medical switching from originator Humira to biosimilar in IBD found that 30-month treatment persistence was 88.2% in the biosimilar group compared to 83.7% in the originator group (P = 0.451) - a difference that was not statistically significant (5). Rates of loss of response and adverse events were comparable between the two groups.

The 2025 SUSTAIN multicenter study went further, examining what happens when patients are switched more than once between different adalimumab products. The results were reassuring: 95.4% of IBD patients maintained sustained clinical remission after a single biosimilar switch, and 93.6% maintained remission after multiple switches, with no treatment-emergent adverse events, infections, or treatment discontinuations reported (6).

Managing the Nocebo Effect and Patient Anxiety

One important factor to be aware of is the nocebo effect - the phenomenon where expecting a switch to cause problems can itself drive symptom reports, even when the drug is pharmacologically the same. This is well documented in biosimilar switching studies and is not a sign of weakness or imagination. Open, honest patient education about what the biosimilar switch involves can significantly reduce nocebo-driven discontinuation.

When being switched, questions worth asking your team include: which specific biosimilar am I receiving, how do I reach the manufacturer's patient support program, how should I report any new symptoms, and is the injection device different from what I have been using?

Living Well on Humira: Practical Patient Guidance

Starting a biologic is one decision - staying on it successfully over months and years is where the real work happens.

When Humira Stops Working (Loss of Response)

Loss of response to adalimumab is common over time. If your symptoms begin creeping back despite regular dosing, your doctor may order therapeutic drug monitoring - blood tests that measure the level of adalimumab in your system and check for anti-drug antibodies that can neutralize the medication. Based on those results, your team might recommend dose escalation (moving to weekly injections), switching to another anti-TNF, or switching to a different class of biologic entirely. For a deeper look at how this testing works, see our therapeutic drug monitoring guide.

Combining Humira with Other Treatments

Adalimumab is sometimes used in combination with an immunomodulator like azathioprine or methotrexate. Adding an immunomodulator can reduce the formation of anti-drug antibodies - which helps the biologic stay effective for longer. However, this combination must be balanced against the small additional risk of HSTCL, particularly in younger male patients. Your GI team will weigh the benefits and risks based on your specific situation.

Vaccinations, Pregnancy, and Daily Life

Non-live vaccines, including the annual influenza shot, COVID-19 boosters, and the non-live shingles vaccine (Shingrix), are recommended while on adalimumab. Live vaccines should generally be avoided during treatment.

Adalimumab has one of the longest safety track records of any biologic in pregnancy. It is often continued through pregnancy after shared decision-making between the patient, their gastroenterologist, and their obstetrician, because uncontrolled Crohn's during pregnancy carries its own significant risks. If you are planning a pregnancy, bringing this up with your GI team early allows time for a thoughtful plan.

In day-to-day life, keeping a log of your injection dates, symptoms, and any side effects can be genuinely helpful. Bring this record to your gastroenterology visits so any early signs of loss of response are caught before they become full-blown flares.

Frequently Asked Questions

How quickly does Humira start working for Crohn's disease?

Some patients notice improvement within the first two to four weeks of starting adalimumab, but the full induction period is typically assessed around week 4 to 8. In the SERENE-CD trial, clinical remission at week 4 was 44% (2). However, the full benefit of maintenance therapy may take several months to become apparent, so patience and consistent dosing are important.

Can I drink alcohol while taking Humira?

There are no absolute contraindications to moderate alcohol consumption while on adalimumab, but alcohol can irritate the gut and may worsen Crohn's symptoms independently. Many of us in the Crohn's community find that moderation works best. Discuss your specific situation with your doctor, especially if you are on combination therapy with an immunomodulator, since some of those medications affect the liver.

What happens if I develop antibodies to adalimumab?

Anti-drug antibodies can reduce the effectiveness of adalimumab by clearing it from your body faster. If therapeutic drug monitoring reveals high antibody levels and low drug levels, your doctor may recommend switching to a different anti-TNF (like infliximab) or to a biologic in a different class (like ustekinumab or risankizumab). Adding an immunomodulator can help prevent antibody formation in the first place, which is why some doctors start combination therapy early.

Is Humira safe during pregnancy?

Adalimumab has one of the longest safety records among biologics in pregnancy and is often continued through pregnancy after shared decision-making. Active Crohn's disease during pregnancy is associated with increased risks of preterm birth, low birth weight, and other complications, so maintaining remission is generally the priority. Your gastroenterologist and obstetrician can work together to determine the best approach for your specific situation.

Will switching to a biosimilar change how my treatment works?

Clinical evidence consistently shows that switching from originator adalimumab to a biosimilar does not meaningfully change treatment outcomes. The 2025 SUSTAIN study found 95.4% sustained remission after a single switch and 93.6% after multiple switches (6). The injection device may differ between products, so ask your nurse or pharmacist to walk you through the new device before your first dose.

How do I manage injection site reactions?

Injection site reactions - redness, swelling, itching, or mild pain at the injection spot - are the most common side effect and usually improve over time. Letting the medication reach room temperature before injecting, rotating injection sites, and injecting slowly can all help. Applying ice to the area before the injection can numb the skin. If reactions are persistent or severe, let your care team know.

What should I do if I miss a dose of Humira?

Inject the missed dose as soon as you remember, then continue your regular every-other-week schedule from that point forward. Do not take a double dose to make up for the one you missed. Setting a recurring calendar reminder or phone alarm for your injection days can help prevent missed doses, especially during busy periods or travel.

References

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007. Read study
2. D'Haens GR, Sandborn WJ, Loftus EV Jr, et al. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology, 2022;162(7):1876-1890. Read study
3. Loftus EV Jr, D'Haens G, Rutgeerts P, et al. Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn's Disease: Results of the PYRAMID Registry. Inflammatory Bowel Diseases, 2019. Read study
4. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut, 2009. Read study
5. Liu Chen Kiow J, et al. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. World Journal of Gastroenterology, 2024. Read study
6. Shehab M, et al. Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. Journal of Clinical Medicine, 2025. Read study
7. Crohn's & Colitis Foundation. Adalimumab - patient medication page. Read article